R3HDM1 and cancer: Overall, this investigation aims to establish R3HDM1 as a promising molecular marker for predicting cancer patient outcomes and assessing the efficacy of immunotherapeutic interventions, thereby contributing to the development of more effective cancer treatments and potentially novel anti-tumor therapies.